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Abstract 
Background: Vaccines are the most reliable alternative to elicit sterile immunity against malaria but their develop‑
ment has been hindered by polymorphisms and strain‑specificity in previously studied antigens. New vaccine candi‑
dates are therefore urgently needed. Highly conserved Plasmodium falciparum reticulocyte‑binding protein homo‑
logue‑5 (PfRH5) has been identified as a potential candidate for anti‑disease vaccine development. PfRH5 is essential 
for erythrocyte invasion by merozoites and crucial for parasite survival. However, there is paucity of data on the extent 
of genetic variations on PfRH5 in field isolates of Plasmodium falciparum. This study described genetic polymorphisms 
at the high affinity binding polypeptides (HABPs) 36718, 36727, 36728 of PfRH5 in Nigerian isolates of P. falciparum. 
This study tested the hypothesis that only specific conserved B and T cell epitopes on PfRH5 HABPs are crucial for vac‑
cine development.
Methods: One hundred and ninety‑five microscopically confirmed P. falciparum samples collected in a prospective 
cross‑sectional study of three different populations in Lagos, Nigeria. Genetic diversity and haplotype construct of 
Pfrh5 gene were determined using bi‑directional sequencing approach. Tajima’s D and the ratio of nonsynonymous vs 
synonymous mutations were utilized to estimate the extent of balancing and directional selection in the pfrh5 gene.
Results: Sequence analysis revealed three haplotypes of PfRH5 with negative Tajima’s D and dN/dS value of − 1.717 
and 0.011 ± 0.020, respectively. A single nucleotide polymorphism, SNP (G → A) at position 608 was observed, which 
resulted in a change of the amino acid cysteine at position 203 to tyrosine. Haplotype and nucleotide diversities were 
0.318 ± 0.016 and 0.0046 ± 0.0001 while inter‑population genetic differentiation ranged from 0.007 to 0.037. Five 
polypeptide variants were identified, the most frequent being KTKYH with a frequency of 51.3%. One B‑cell epitope, 
151 major histocompatibility complex (MHC) class II T‑cell epitopes, four intrinsically unstructured regions (IURs) and 
six MHC class I T‑cell epitopes were observed in the study. Phylogenetic analysis of the sequences showed clustering 
and evidence of evolutionary relationship with 3D7, PAS‑2 and FCB‑2 RH5 sequences.
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Background
The pathology associated with Plasmodium falcipa-
rum malaria is elicited by erythrocyte invasion during 
the asexual stage of parasite development, which is an 
important target for vaccine development [1]. Owing to 
the widespread of multi-drug resistant strains of P. falci-
parum in malaria endemic regions, vaccines may be the 
reliable intervention strategy to mount sterile immu-
nity against malaria through both humoral and T-cell 
responses.
The newly introduced malaria vaccine, the RTS, S/
ASO1 (RTS,S), recently recommended by the World 
Health Organization (WHO) elicits some protective 
effect against malaria. However, its field efficacy is limited 
to 39% among children with uncomplicated malaria and 
29% in severe malaria cases and only protective against 
P. falciparum [2]. The field efficacies of vaccine against 
P. falciparum, the deadliest species of malaria parasite, 
have been significantly hampered by genetic polymor-
phisms in candidate antigens. These polymorphisms alter 
the epitope expression leading to loss of vaccine efficacy 
[3], hence vaccines designed with sequence compositions 
identical to the infecting parasites can offer protection 
against infections by such parasites [4, 5].
Population genetic analysis of vaccine candidate anti-
gens offers an insight into the extent and dynamics of 
genetic polymorphisms and guides vaccine design [4]. 
This often involves investigation of location and distribu-
tion of these genetic variations. However, genetically dis-
tinct P. falciparum strains involved in the development of 
strain-specific immunity are most likely carried by indi-
viduals living in malaria endemic areas [4, 6, 7].
Chemotherapy, host immunity and intensity of compe-
titions within hosts impose selection pressure on vaccine 
candidate antigens [8]. Epidemiological survey of genetic 
diversity associated with P. falciparum at study sites for 
vaccine trials is utilized in molecular identification of 
prevalent genetic variants of vaccine candidate proteins 
[4]. Plasmodium falciparum reticulocyte binding-like 
protein family (PfRH) has been in the focus for vaccine 
development because it is a key determinant of erythro-
cyte invasion [9]. Plasmodium falciparum Rh comprises 
of five members: PfRH1, PfRH2a, PfRH2, PfRH4 and 
PfRH5. PfRH5 is currently a promising vaccine candidate 
antigens fast approaching clinical development [9]. Most 
of the clinical manifestations in malaria is as a result of 
erythrocyte invasion, which is a complex process involv-
ing merozoite attachment to red blood cell (RBC), re-ori-
entation, tight junction formation and parasite entry into 
the RBC. The receptor PfRH5 on the RBC is Basigin (CD 
147).
PfRH5 is a 63-kD protein, encoded by the rh5 gene 
located on chromosome 4. The protein is located at the 
tight junction together with its associated binding pro-
teins, AMA1 and RON2. PfRH5 lack trans-membrane 
domain in its sequence, its binding with AMA1 and 
RON2 may be important for its membrane anchorage. 
Antibodies against PfRH5 from different parasite strains, 
inhibited the growth of different strains of P. falciparum, 
out-performing other antigens on the vaccine develop-
ment platforms [9].
Nonetheless, limited genetic polymorphisms have been 
reported on pfrh5 gene, however, these SNPs signifi-
cantly modify the protein affecting its binding to basigin 
and in the active complex. Certain peptides in PfRH5 
have been identified as having high red blood cell bind-
ing affinity (HABPs) [10]. They include the HABPs 36718, 
36727 and 36728 in which genetic mutations affect the 
protein structure of the whole PfRH5 protein [10]. Cur-
rently, a total of five informative non-synonymous SNPs 
have been reported in PfRH5 [10] but there is a paucity of 
information on PfRH5 polymorphisms among P. falcipa-
rum isolates circulating in most African countries.
This cross-sectional study aimed to evaluate the status 
and extent of polymorphisms in PfRH5 HABPs 36718, 
36727 and 36728 among P. falciparum isolates from 
Lagos, Nigeria. The study also investigated the presence 
of B- and T-cell epitopes that are immunologically impor-
tant with respect to effective malaria vaccine design.
Methods
Sampling and study design
In this cross-sectional study, participants were recruited 
at the peak of malaria transmission from March to Sep-
tember 2016 at three health facilities in Lagos State, 
South-West Nigeria. The study areas included (a) Ijede 
General Hospital, Ijede, (b) Ajeromi General Hospi-
tal, Ajegunle, (c) St. Kizito’s Primary Healthcare Centre, 
Conclusions: This study has revealed low level of genetic polymorphisms in PfRH5 antigen with B‑ and T‑cell 
epitopes in intrinsically unstructured regions along the PfRH5 gene in Lagos, Nigeria. A broader investigation is 
however required in other parts of the country to support the possible inclusion of PfRH5 in a cross‑protective multi‑
component vaccine.
Keywords: Polymorphisms, Reticulocyte‑binding protein homologue‑5, Haplotypes, Histocompatibility, Gene flow, 
Linkage, Unstructured regions
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Lekki (Fig. 1a). Malaria transmission is high in these areas 
and occurs all-year round, the selected facilities have 
over 500 outpatients per week. Informed consent (paren-
tal consent and/or assent from under-16 participants) 
were obtained from the patients presenting at these 
centres with symptoms suggestive of malaria (axillary 
temperature ≥ 37.5 or history of fever in the last 48  h). 
Participants with P. falciparum mono-infection (infec-
tion by P. falciparum alone as confirmed by microscopy 
and pan-specific SD Bioline malaria rapid diagnostic test 
kit, Wagle, India) and a minimum of 2000 P. falciparum 
parasites/µL estimated by thick film examination were 
enrolled into the study, after which they were treated 
with artemether-lumefantrine according to national 
guidelines [11]. Finger-pricked blood samples collected 
from the participants (Fig.  1b) were used to prepare 
smears according to WHO standard protocol [12].
The slides were independently read by two micros-
copists for the estimation of parasite densities and spe-
cies determination using the thick and thin blood films, 
respectively, assuming an average white blood cell count 
of 8000/μL. gDNA extraction, parasite genotyping and 
polymerase chain reaction (PCR) Amplification of pfrh5 
gene were done at the Malaria Research and Immunol-
ogy Laboratory of the Nigerian Institute of Medical 
Research, Lagos, Nigeria. DNA re-amplification, cleaning 
and sequencing of pfrh5 were done at the Department 
of Biomedical Chemistry, Graduate school of Medicine, 
University of Tokyo, Tokyo, Japan.
DNA extraction and parasite clonal differentiation
Extraction of whole-blood genomic DNA (gDNA) was 
carried out using QIAGEN  QIAamp® DNA Extraction 
mini-kit (Qiagen, UK, CAT NO: 51306) from the indi-
vidual dried blood spots. The extracted DNA samples 
were stored at − 20  °C until PCR. The quality as well 
as quantity of each DNA sample was determined using 
Nanodrop 1000 (Thermo Fisher Scientific, USA). To dif-
ferentiate the parasites based on clonal origin, oligonu-
cleotide primers (MSP2-OF:5′-ATG AAG GTA ATT AAA 
ACA TTG TCT ATT ATA -3′ and MSP2-OR: 5′-CTT TGT 
TACC-ATC GGT ACA TTC TT-3′ for the primary reac-
tion. The secondary reactions involved: FC27-OF:5′-AAT 
ACT AAG AGT GTA GGT GCA RAT GCT CCA -3′ and 
FC27-OR: 5′-TTT TAT TTGGT GCA TTG CCA GAA 
CTT GAA C-3′, IC/3D7M2-F: 5′ AGA AGT ATGG-CAG 
AAA GTAAK CCT YCT ACT-3′and IC/3D7M2-R:5′-GAT 
TGT AAT TCG GGG GAT TTG TTC G-3′ from published 
sequences in the GenBank [13], were used to amplify 
the block 3 of MSP-2 in nested-PCR. The conditions for 
the primary reactions were an initial denaturation step 
at 95  °C for 5  min, followed by 30 cycles consisting of 
1 min of denaturation step at 94  °C, 2 min of annealing 
at 55  °C, and 2 min of extension at 72  °C, followed by a 
final extension at 72 °C for 5 min. The same cycling con-
ditions were used for the secondary PCR (Nest 2) reac-
tion except that the extension in the cycle was for 1 min. 
The DNA regions were amplified in 50 µL reaction mix-
tures containing: 1.25  U PfuUltra II Fusion HS DNA 
polymerase (Agilent Technologies, Santa Clara, USA), 
1× polymerase reaction buffer, 2.5 mM  MgCl2, 0.25 mM 
dNTPs and 1 µM of each primer. Each amplification with 
conserved or family-specific primer pair being done sep-
arately as previously described [14], using 2 μL of 5 ng/
μL DNA sample. PCR products were electrophoresed on 
1.5% agarose gels, and DNA bands visualized with the gel 
documentation system (Infinity 3026, Vilber Lourmat, 
Marne-la-Vallée, France) after ethidium bromide stain-
ing. The sizes of the fragments obtained were estimated 
by comparison to the 1.3 Kb (100 bp) DNA ladder (Jena 
Bioscience GmbH, Germany) as marker in comparison 
with standard purified genomic DNA from 3D7 labora-
tory strains similarly electrophoresed.
Amplification of pfrh5 gene
Plasmodium falciparum reticulocyte binding protein 
homologue 5 (pfrh5) gene was amplified from the whole-
blood genomic DNA of samples with single parasite line 
using the primer set sequences namely: RH5-F1: 5′-ACC 
CAT GAG GAA TTG AGT C-3′ and RH5-R1: 5′-CGG 
TTT CAT CAT CTG TCT C-3′ amplifying the exon region 
encoding HABPs 36718, 36727 and 36728 [10]. The 
cycling parameters for the PCR were: 10 min initial dena-
turation at 94 °C followed by 35 cycles of 1 min denatura-
tion at 94 °C, 1 min annealing at 55 °C, 2 min extension at 
72 °C and a 10 min final extension at 72 °C. All PCR reac-
tions were carried out with 2 μL of DNA in a total volume 
of 50 μL containing 0.2 mM dNTPs, 2 mM  MgCl2, 1 μM 
of each primer, and 1 unit of PfuUltra II Fusion HS DNA 
polymerase (Agilent Technologies, Santa Clara, USA). 
The gel slices containing the DNA fragment of interest 
were excised and purified with the MagExtractor- PCR & 
Gel Clean up kit (TOYOBO Co. LTD., Osaka, Japan).
The purified DNA was sequenced using both forward 
and reverse primers after precipitation using an ABI3777 
automatic DNA sequencer (Applied Biosystems). After 
sequencing, the gene sequences were edited using the 
Bioedit software and aligned amongst themselves using 
CLUSTAL W in MEGA 6 [15]. Blast searches were done 
to compare the RH5 haplotypes with the correspond-
ing sequences available in the Genbank database and 
also with P. falciparum 3D7 reference RH5 sequence 
(GenBank accession number XM_001351508.1). The 
sequences were deposited in the GenBank database of 
NCBI (National Centre for Biotechnological Informa-
tion) (GenBank: KX418644–KX418646).
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Fig. 1 a Geographical location of the three study sites. b Participant sampling
Page 5 of 12Ajibaye et al. Malar J            (2020) 19:6 
Genetic analyses
The number of segregating sites (S), observed nucleotide 
diversity per site between any two sequences assuming 
that the samples are random was estimated as (∏), num-
ber of haplotype (H: uninterrupted sequence of nucleo-
tides or amino acid sequence variants using the PfRH5 
locus of the P. falciparum 3D7 strain (GenBank accession 
number: XM_001351508.1) as the reference sequence for 
all the comparisons), number of mutations, haplotype 
diversity (Hd), Tajima D (positive values show excess of 
alleles and balancing selection), the ratio of the rate of 
non-synonymous to synonymous mutations (dN/dS) (≪1 
values are indication of negative selection), Linkage dis-
equilibrium, haplotype prevalence, Estimate of recom-
bination effect ‘R’ between adjacent sites (to assess the 
rate of recombination which may influence Tajima’s D) 
were determined using DnaSP version 5.10.1 while phy-
logenetic analysis was done by neighbour-joining (NJ) 
method with Kimura-2-parameter distance matrix in 
MEGA 6.
Immunological epitopes (B‑ and T‑cell)
The ABC predserver [16] using a threshold of 0.81 and 
the Human Leukocyte antigens (HLA) binding predic-
tion algorithm (Tmhc Prediction server) were used to 
predict the PfRH5 linear B-cell epitopes and screen the 
PfRH5 sequences for potential CD4 +/CD8 + epitopes 
with respect to related HLA. Major histocompatibil-
ity complexes (MHC-I and MHC-II) display specificity 
for binding with their respective epitopes. In humans, 
these MHC molecules are known by HLA alleles. The 
HLA binding peptides were predicted (threshold set-
ting = 3.000) using the Tmhc Pred server. This prediction 
is based on the virtual and quantitative matrices based on 
97 MHC alleles using position specific scoring matrices 
(PSSMs) and utilizes supervised learning method called 
support vector machine [16]. The relative binding abil-
ity of the different peptides to specific MHC molecule 
were assessed. The peptide concentrations that leads to 
50% inhibition, IC50, were taken. The top binders with 
the cut-off value of IC50 < 100  nM were shortlisted and 
those with IC50 < 50 nM selected to check the potential 
impact of the SNPs with respect to alteration of the core 
sequences of lead epitopes.
The intrinsically unstructured regions (IURs) were 
screened using the Biocomputing package for Accurate 
Detection of Protein Disorder (Cspritz) server [17].
Results
Demographic profile of patients
Three hundred and eighty-four febrile subjects com-
prising 185 males and 199 females were positive for P. 
falciparum malaria out of the 1883 examined in the 
three study areas. Of the 384 microscopically confirmed 
malaria patients, 41.93% were < 5  years, 300 (100 per 
site) were included in this study. Overall, median age was 
10 years and prevalence of P. falciparum malaria among 
the febrile participants was 20.39% ordered as Ijede > Aje-
romi > Lekki (Table 1). Approximately 36.25% of the unin-
fected healthy controls included were < 5 years (Table 1). 
Three hundred individuals (≥ 1 year old) were randomly 
selected for genetic analysis.
Parasite clonal distribution
Of the 300 isolates included in this study, 195 were 
PCR positive for MSP2 (showing bands for one or both 
families). Quality assessment of the extracted DNA 
showed an average yield of 80 ng/µL and purity 1.86 (OD 
260/280). Nested PCR analysis of the MSP-2-confirmed 
samples revealed that both 3D7 and FC27 families of P. 
falciparum MSP-2 were present in the study sites (Fig. 2).
Polymorphisms and haplotypic variations of PfRH5
Analysis of the HABPs 36718, 36727 and 36728 of PfRH5 
revealed 810  bp sequence (encoding amino acid resi-
dues 23–241 of PFRH5) of which 795 sites were invari-
able or monomorphic and 15 (1.85%) were polymorphic 
(6 singleton and 9 parsimony informative) sites. A total 
of 5 non-synonymous SNPs were found in the popula-
tions studied described as: K62R, T81Q, P197S, C203Y 
and H240R with the mutation C203Y being the most 
prevalent with 74.87%. Of these resultant 5 amino acid 
changes, 7 peculiar polypeptide variants were observed, 
and defined based on the amino acid composition at 
the 5 variable residue positions with the most frequent 
variant (variant 1: KTKYH) having a frequency of 51.3% 
and the least (variant 7: ENKCR) with a frequency of 
0.5% (Table 2). Three different RH5 haplotypes (H1, H2 
and H3) were found among the P. falciparum popula-
tions studied based on these variants (Table 4). A single 
nucleotide change (G608A) was observed in the major 
polymorphic nucleotide of PfRH5, HABP 36727, (accord-
ing to the 3D7 reference strain numbering) correspond-
ing to amino acid change at residue 203 from Cysteine 
to Tyrosine (Additional file  1: Table  S1). The haplotype 
diversity (Hd), nucleotide diversity (π) and average num-
ber of pairwise nucleotide differences within population 
showed no clear evidence of regional variation (Table 3). 
The sequences reported in this study have been depos-
ited in the database (GenBank: KX418644–KX418646). 
Phylogenetic analysis showed evolutionary relationship 
of the haplotypes with reported PfRH5 around the world 
(Fig. 3) using Plasmodium reichenowi as the out-group.
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Plasmodium falciparum genetic structure, evidence 
of selection and recombination
The LD (Fig.  4) and dN/dS values for PfRH5 showed 
negative selection with negative values for Tajima’s D and 
values < 1 for dN/dS (Table 3). Based on the three PfRH5 
haplotypes (H1, H2 and H3), inter-population nucleotide 
differences (Kxy) varied from 10.662 (between Ijede and 
Ajeromi) to 11.939 (between Lekki and Ajeromi). Simi-
larly, the average number of nucleotide (Dxy) and net 
nucleotide substitution per site (Da) between populations 
ranged from 0.0233 to 0.0261 and 0.00015 to 0.00096, 
respectively (Table 4).
Table 1 Demographic profile of study population
Overall, prevalence of malaria among the febrile participants was 20.39%, in the ordered Ijede > Ajeromi > Lekki
a Mean value ± SD
Profile Ijede Lekki Ajeromi Total
Number of patients tested for P. falciparum malaria 480 616 787 1883
Number of patients microscopically positive for malaria 114 117 153 384
Prevalence of symptomatic malaria (%) 23.75 18.99 19.44 20.39
Sex of participants
 Test
  Male 61 54 70 185
  Female 63 55 81 199
 Control
  Male 11 14 15 40
  Female 11 14 15 40
Participants age groups
 Test (years)
  < 5 32 51 78 161
  ≥ 5 82 66 75 223
 Control (years)
  < 5 8 10 11 29
  ≥ 5 14 18 19 51
Parasite density (parasite/μL) (years)
 < 5 145,629 128,302 134,870 136,267 ± 8748.23a
 ≥ 5 45,595 20,040 33,101 32,912 ± 12,778.54a
Fig. 2 Distribution of MSP2 alleles in isolates from the sites studied
Table 2 Frequency of 7 PfRH5 variants of 5 SNPs in Nigerian isolates
Polypeptide Variant K62R T81Q K197N C203Y H240R Frequency (%)
KTPYH 1 K T K Y H 51.3
RQNCR 2 R Q N C 24.0
KTPYR 3 K Y 20.2
KTPYH 4 Y 2
KTPCH 5 C 1
KTPNR 6 N 1
ENPCR 7 R 0.5
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Fig. 3 Molecular phylogenetic analysis of RH5 haplotypes by Maximum Likelihood method. A neighbour‑joining (NJ) tree depicting the 
relationship between different RH5 haplotypes observed among Nigerian P. falciparum populations and with other RH5 sequences including PAS‑2, 
FCB‑2, 7G8 and 3D reference strain RH5. The evolutionary history was inferred by using the Maximum Likelihood method. The analysis involved 
78 nucleotide sequences. Numbers below the lines indicate percentage bootstrap values for 1000 replications. All positions containing gaps and 
missing data were eliminated. Evolutionary analyses were conducted in MEGA6 [15]. The RH5 sequence of Plasmodium reichenowi was used as an 
out‑group
Fig. 4 Linkage disequilibrium (LD) plot showing non‑random association between nucleotide variants at different polymorphic sites on RH5. The 
 R2 values are plotted against the nucleotide distances with two‑tailed Fisher’s exact test of significance using DnaSP. The value of LD index (range 
from − 1 to +1) increased with increasing distance, indicating no recombination events taking place. All polymorphic sites were considered in the 
analysis. a Ajeromi, b Lekki, c Ijede, d total
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Variability of Immunological (B‑ and T‑cell) epitopes 
in PfRH5
To investigate the representativeness of specific predicted 
epitopes on the basis of their immunological significance, 
in comparison with the complete active PfRH5 pro-
tein, B- and T-cell epitopes and the IURs were screened 
for genetic mutations. This analysed the complexity 
of genetic diversity of predicted epitopes. One B-cell 
epitope, 151 MHC class II T-cell epitopes, four IURs 
(highly disordered) and six MHC class I T-cell epitopes 
were observed (Fig. 5, Table 5). Two out of the 5 genetic 
mutations in the pfrh5 genes were found located in the 
epitope region, however, there was no commitment to 
populating genetic mutations in epitope regions along 
the gene sequences mapping the pfrh5 HABPs  (x2 = 6.72, 
P = 0.062, df = 2). A large part of the gene sequences was 
conserved, of which some of the epitopes were located in 
the disordered region of the protein (Fig. 5).
Discussion
In natural P. falciparum populations, one major hin-
drance to effective vaccine design and development is the 
sequence variation on the surface of vaccine candidate 
proteins. Therefore, a vaccine targeting a single allelic 
form of parasite proteins cannot elicit required protective 
immunity [18].
The difficulty of developing an effective malaria vaccine 
is largely due to polymorphisms in candidate proteins 
resulting strain-specificity and failed field trials. However, 
PfRH5 is highly susceptible to cross-strain neutralizing 
vaccine-induced antibodies, and out-performs all other 
antigens delivered by vaccine platforms [19, 20]. More-
over, only limited polymorphisms have been reported 
in PfRH5. Hence, there is need for population-specific 
investigation of sequence diversity of PfRH5 in Nigeria to 
inform design of effective vaccine.
This study investigated the extent of polymorphisms in 
P. falciparum RH5 in Lagos, Nigeria to improve under-
standing of the population-specific processes of acquired 
immunity and vaccine failure.
HABPs 36718, 36727 and 36728 of PfRH5 were geneti-
cally analysed from Nigerian isolates. Among the genetic 
mutations and amino acid changes found, five non-syn-
onymous SNPs were observed giving rise to 5 polypep-
tide variants with frequencies ranging from 51.3 to 84.9%.
Genetic analysis of the 810  bp PfRH5 sequences 
revealed that Tajima’s D and dN/dS values for PfRH5 
Table 4 Inter-population genetic differentiation of P. falciparum 
a Average number of nucleotide differences between populations
b The average number of nucleotide substitutions per site between populations
c The net nucleotide substitutions per site between populations
d Fixation index, a measure of genetic differentiation between population (range from 0 to + 1)
S/N Population 1 Population 2 Kxya Dxyb Dac Fstd
1 IJEDE LEKKI 11.535 0.0252 0.00089 0.035
2 IJEDE AJEROMI 10.662 0.0233 0.00015 0.007
3 LEKKI AJEROMI 11.939 0.0261 0.00096 0.037
Fig. 5 Distribution of SNPs, B‑ and T‑cell epitopes on PfRH5 from Nigerian P. falciparum 
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were negative suggesting a purifying selection on this 
gene. Consequent upon the very low polymorphisms in 
this gene, there is a high tendency for susceptibility of 
Nigerian isolates of P. falciparum to universally effec-
tive vaccines based on PfRH5 [21] reported a rationale to 
advance PfRH5-based vaccine to the Phase I/IIa human 
trials, which if successful, could be combined with vac-
cines targeting other stages of the P. falciparum life cycle, 
such as the sporozoite stage in the RTS, S vaccine. This 
promises a good efficacy of such vaccines going by the 
results from this study.
Phylogenetic analysis revealed clustering of the hap-
lotypes and evolutionary relationship of the haplotypes 
with the reference 3D7 and other reported strains includ-
ing the PAS-2, FCB-2 RH5 sequences [21]. It has been 
clearly demonstrated that evolutionary analysis may help 
explain changes in tropism when information on the 
location and nature of functional genetic variation are 
provided [22, 23].
The low Fst values suggest high gene flow between 
two populations in the study sites. This means that any 
allele introduced spreads fast among the P. falciparum 
populations with a negative impact on control meas-
ures if it is undesirable.
However, this also implies that interbreeding occurs 
more freely between 2 populations, as studied, which 
is consistent with the finding of three RH5 haplotypes. 
Thus, HABP 36727, with no clear evidence of regional 
variation indicates that most of the malaria infections 
were actually originating from strains circulating inside 
Lagos, suggesting limited chances of finding indications 
of PfRH5 polymorphisms. This has been observed as a 
potential limitation of this study.
Apart from immunity, occurrence of ancillary causes 
of selection which may operate on the parasite at other 
stages of development, is an important limitation of 
applying genetic technique [21]. These may include rap-
idly increased frequency of antigenic alleles at a locus 
which occasionally occurs per chance and may be indis-
tinguishable from selection events. Alleles existing at a 
locus for a period of time can acquire individual sets of 
neutral mutations that are unique unless recombination 
events occur causing linkage between the functionally 
different alleles.
An important factor to consider in the selection 
of PfRH5 for involvement in the multi-component 
malaria vaccine design is the location of epitopes, in 
conserved regions or/and intrinsically unstructured 
regions (IURs) of the protein [22, 24]. IURs are impor-
tant targets of host immune system, including antibody 
recognition. Disordered epitopes are usually smaller, 
but more efficient and sensitive to epitope sequence 
variations [24]. It is therefore imperative to identify 
population-specific polymorphic immunological hot-
spots within the disordered antigen–antibody interface 
from our study population. Although C203Y mutation 
was most frequent, only one of the codons (197) within 
the PfRH5–basigin interface was observed to be poly-
morphic. These findings show a high level of conserva-
tion of PfRH5 in comparison with the expectations for 
a protein with such critical functional role. However, 
the presence of polymorphisms in the predicted immu-
nologically important peptide requires further atten-
tion to understand the impact on the effectiveness of 
PfRH5-based vaccine.
This study revealed epitopes that are conserved and 
located in disordered regions on the RH5 sequences 
from Lagos Nigeria. The inhibition activity of these 
epitopes or fragments should be assessed by functional 
assays to ascertain their biological and immunologi-
cal relevance as candidate epitopes of a PfRH5-based 
vaccine.
Table 5 Predicted CD8 + T-cell, CD4 + T-cell, and  B-cell 
epitopes in PfRH5 (IC50 < 50 nM)
Allele Predicted peptide IC50 Number 
of polymorphic 
sites
T‑cell epitopes
 Class II
  DRB1_1304 LNTNVNDAL 8.72 0
TNVNDALKY 30.21 0
  DRB1_0701 YLFIPSHNS 12.81 0
FKELSNYNI 27.83 0
YNIANSIDI 46.31 0
YKHLYSNCI 47.83 0
YIAVDAFIK 48.32 1
  DRB1_1101 LTLLTIQST 21.37 0
IKSYLNTNV 41.22 0
FIKKYSVFN 44.67 0
FNQINDGML 48.35 0
FKELSNYNI 48.56 0
YGKYIAVDA 48.64 1
  DRB1_0120 FNQINDGML 31.84 0
YNIANSIDI 37.21 0
LKYLFIPSH 45.57 0
YKHLYSNCI 47.87 0
 Class I
  HLA‑A*30:01 KTKNQENNL 14.79 0
IAVDAFIKK 15.87 0
KVKSKTNET 36.71 0
SVIIPHYTF 29.00 0
  HLA‑B*35:01 PHYTFLDY 15.36 0
FIKKINETY 40.42 0
B‑cell epitope PSHNSFIKKYSV 0
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Recognition of a peptide by T cells requires a num-
ber of steps, most notably the binding of the peptide to 
a host-encoded HLA molecule. It was also observed 
that not significant number of SNPs were found on the 
epitope regions of PfRH5, which could be inferred to 
reveal no categorical commitment to populating poly-
morphisms along these regions. However, larger study 
populations may be required to confirm this finding.
Conclusion
Globally efficacious RH5-based vaccine may be consider-
ably protective in Nigeria in spite of the complex genetic 
diversity of Nigerian isolates of P. falciparum. Identi-
fication of variants herein reported, is suggestive of the 
necessity of a wider coverage of studies on the potential 
efficacy of PfRH5-based vaccine in the study commu-
nities in relation to the spatial distribution of immuno-
logically significant genetic mutations in isolates from 
Nigeria.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1293 6‑019‑3096‑0.
Additional file 1: Table S1. Mutations in PfRH5 sequences from Lagos, 
Nigeria.
Abbreviations
RH5: reticulocyte‑binding protein homolog 5; gDNA: genomic deoxyribonu‑
cleic acid; HABPs: high affinity binding polypeptides; LD: linkage disequilib‑
rium; MHC: major histocompatibility complex; HLA: human leukocyte antigen; 
IUR: internally unstructured regions; MEGA: Molecular Evolutionary Genetics 
Analysis.
Acknowledgements
The authors are grateful to the patients who contributed samples for this 
study, and to the staff, nurses and doctors of the hospitals visited who 
facilitated sample collection. Our sincere gratitude and appreciations go to 
Department of Biomedical Chemistry, The University of Tokyo for the immense 
contribution to the gene sequencing aspect of this study. We are grateful to 
the patients who contributed samples for this study and Authors appreciate 
the Department of Microbiology of the Nigerian Institute of Medical Research, 
Nigeria for their support. EOB is a FLAIR Research Fellow of The Royal Society, 
UK, and supported by a Global Challenge Research Fund (GCRF) Grant (No. 
FLR\R1\190353) through a partnership between the African Academy of Sci‑
ences and the Royal Society, UK.
Authors’ contributions
OA conceived the study and carried out the laboratory and molecular analysis. 
AAO and EOB supervised the work and revised the manuscript, BAI, KH and 
OA handled data analysis and interpretation. OA wrote the manuscript. KMO, 
YW, GUE, KK and AA revised the manuscript. All authors read and approved 
the final manuscript.
Funding
This work was funded personally.
Availability of data and materials
All data generated or analysed during this study are included in this published 
article. The nucleotide sequences of P. falciparum RH5 gene obtained from 
this study have been submitted in GenBank database under the Accession 
Numbers: KX418644–KX418646.
Ethics approval and consent to participate
Ethical approval (Ref No: IRB/10/136) to conduct this study was obtained from 
the Institutional Review Board of the Nigerian Institute of Medical Research, 
Lagos. Permission was obtained from the different health facilities where the 
study was carried out. All the research participants gave written informed 
consent, guardian/parental consent and/or accent for participants less than 
16 years (children). The adults provided written informed consent and the 
parents/guardians gave informed consent on behalf of their children/wards. 
Participants who declined participation were not denied treatment. Generally, 
the study was conducted in line with the principle of Good Clinical Laboratory 
Practice (GCLP) and the 1994 Helsinki Declaration.
Consent for Publication
Not applicable.
Competing interests
We hereby state that there is no conflict of interest regarding this work. There 
is no financial or non‑financial competing interests.
Author details
1 Department of Biochemistry & Nutrition, Nigerian Institute of Medical 
Research, Yaba, Lagos, Nigeria. 2 Department of Biochemistry, College of Medi‑
cine, University of Lagos, Idi‑Araba, Lagos, Nigeria. 3 Department of Biochem‑
istry, Ahmadu Bello University, 2222 Zaria, Nigeria. 4 Department of Biomedi‑
cal Chemistry, Graduate School of Medicine, The University of Tokyo, 7‑3‑1 
Hongo, Bunkyo‑ku, Tokyo 113‑0033, Japan. 5 Parasitology and Bioinformatics 
Unit, Department of Zoology, Faculty of Science, University of Lagos, Akoka, 
Lagos, Nigeria. 6 Department of Infection and Host Defense, Graduate School 
of Medicine, Chiba University, 1‑8‑1 Inohana, Chuo‑ku, Chiba 260‑8670, Japan. 
7 School of Health and Life Sciences, Teesside University, Middlesbrough TS1 
3BX, UK. 8 School of Tropical Medicine and Global Health, Nagasaki University, 
Nagasaki 852‑8523, Japan. 9 Medical Research Council at the London School 
of Hygiene and Tropical Medicine, Atlantic Boulevard, Fajara, The Gambia. 
Received: 11 August 2019   Accepted: 26 December 2019
References
 1. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of 
malaria. Nature. 2002;415:673–9.
 2. WHO. Malaria vaccine: WHO position paper. Vaccine. 2018;36:3576–7.
 3. Srisutham S, Saralamba N, Sriprawat K, Mayxay M, Smithuis F, Nosten 
F, et al. Genetic diversity of three surface protein genes in Plasmodium 
malariae from three Asian countries. Malar J. 2018;17:24.
 4. Takala SL, Plowe CV. Genetic diversity and malaria vaccine design, testing 
and efficacy: preventing and overcoming ‘vaccine resistant malaria’. 
Parasite Immunol. 2009;31:560–73.
 5. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. 
Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vac‑
cine. N Engl J Med. 2015;373:2025–37.
 6. Kyabayinze DJ, Karamagi C, Kiggundu M, Kamya MR, Wabwire‑Mangen F, 
Kironde F, et al. Multiplicity of Plasmodium falciparum infection predicts 
antimalarial treatment outcome in Ugandan children. Afr Health Sci. 
2008;8:200–5.
 7. Sawyer SA, Parsch J, Zhang Z, Hartl DL. Prevalence of positive selection 
among nearly neutral amino acid replacements in Drosophila. Proc Natl 
Acad Sci USA. 2007;104:6504–10.
 8. Mobegi VA, Duffy CW, Amambua‑Ngwa A, Loua KM, Laman E, Nwakanma 
DC, et al. Genome‑wide analysis of selection on the malaria parasite 
Plasmodium falciparum in West African populations of differing infection 
endemicity. Mol Biol Evol. 2014;31:1490–9.
 9. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman 
AL, et al. The blood‑stage malaria antigen PfRH5 is susceptible to vaccine‑
inducible cross‑strain neutralizing antibody. Nat Commun. 2011;20:601.
 10. Arévalo‑Pinzón G, Curtidor H, Muñoz M, Patarroyo MA, Bermudez A, 
Patarroyo ME. A single amino acid change in the Plasmodium falciparum 
Page 12 of 12Ajibaye et al. Malar J            (2020) 19:6 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
RH5 (PfRH5) human RBC binding sequence modifies its structure and 
determines species‑specific binding activity. Vaccine. 2012;30:637–46.
 11. Federal Ministry of Health. National malaria control programme, 2005 
Annual Report. Abuja: Federal Ministry of Health; 2008.
 12. WHO. Assessment and monitoring of antimalarial drug efficacy for the 
treatment of uncomplicated falciparum malaria. World Health Organiza‑
tion: Geneva, WHO/HTM/RBM/2003.5, 2003.
 13. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identifica‑
tion of the four human malaria parasite species in field samples by the 
polymerase chain reaction and detection of a high prevalence of mixed 
infections. Mol Biochem Parasitol. 1993;58:283–92.
 14. Mayengue PI, Ndounga M, Malonga FV, Bitemo M, Ntoumi F. Genetic 
polymorphism of merozoite surface protein‑1 and merozoite surface 
protein‑2 in Plasmodium falciparum isolates from Brazzaville, Republic of 
Congo. Malar J. 2011;10:276.
 15. Tamura K, Battistuzzi FU, Billing P, Murillo O, Filipski A, Kumar S. Estimating 
divergence times in large molecular phylogenies. Proc Natl Acad Sci USA. 
2012;109:19333–8.
 16. Saha S, Raghava GPS. Prediction of continuous B‑cell epitopes in an 
antigen using recurrent neural network. Proteins. 2006;65:40–8.
 17. Biocomputing package for Accurate Detection of Protein Disorder 
(Cspritz) (http://prote in.bio.unipd .it/cspri tz/). Accessed 23 Dec 2018.
 18. Wright GJ, Rayner JC. Plasmodium falciparum erythrocyte invasion: com‑
bining function with immune evasion. PLoS Pathog. 2014;10:e1003943.
 19. Patel SD, Ahouidi AD, Bei AK, Dieye TN, Mboup S, Harrison SC, et al. 
Plasmodium falciparum merozoite surface antigen, PfRH5, elicits detect‑
able levels of invasion‑inhibiting antibodies in humans. J Infect Dis. 
2013;208:1679–87.
 20. Ouattara A, Tran TM, Doumbo S, Matthew A, Agrawal S, Niangaly A, et al. 
Extent and dynamics of polymorphism in the malaria vaccine candidate 
Plasmodium falciparum reticulocyte‑binding protein homologue‑5 in 
Kalifabougou, Mali. Am J Trop Med Hyg. 2018;99:43–50.
 21. Bustamante LY, Bartholdson SJ, Crosnier C, Campos MG, Wanaguru 
M, Nguon C. A full‑length recombinant Plasmodium falciparum PfRH5 
protein induces inhibitory antibodies that are effective across common 
PfRH5 genetic variants. Vaccine. 2013;31:373–9.
 22. Sironi M, Cagliani R, Forni D, Clerici M. Evolutionary insights into host‑
pathogen interactions from mammalian sequence data. Nat Rev Genet. 
2015;16:224–36.
 23. Otsuk H, Kaneko O, Thongkukiatkul A, Tachibana M, Iriko H, Takeo S, et al. 
Single amino acid substitution in Plasmodium yoelii erythrocyte ligand 
determines its localization and controls parasite virulence. Proc Natl Acad 
Sci USA. 2009;106:7167–72.
 24. Ramamurthy M, Sankar S, Abraham AM, Nandagopal B, Sridharan G. 
B cell epitopes in the intrinsically disordered regions of neuramini‑
dase and hemagglutinin proteins of H5N1 and H9N2 avian influenza 
viruses for peptide‑based vaccine development. J Cell Biochem. 
2019;120(10):17534–44.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
